Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

110.51USD
20 Apr 2018
Change (% chg)

$-1.23 (-1.10%)
Prev Close
$111.74
Open
$111.85
Day's High
$111.85
Day's Low
$109.83
Volume
221,310
Avg. Vol
730,474
52-wk High
$149.17
52-wk Low
$96.18

Select another date:

Thu, Apr 12 2018

Deals of the day-Mergers and acquisitions

April 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Biotech M&A rolls on as Alexion snaps up Wilson for $855 million

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

UPDATE 2-Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

* U.S. company says first step in rebuilding pipeline (Adds latest shares, analyst reaction)

Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

April 11 Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.

BRIEF-Alexion To Acquire Wilson Therapeutics

* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln

* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING

Alexion's second rare blood disorder drug could fortify future revenue

Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms.

BRIEF-Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210

* ALEXION ANNOUNCES POSITIVE TOP-LINE RESULTS SHOWING SUCCESSFUL PHASE 3 CLINICAL STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Alexion's rare blood disorder drug succeeds in late-stage study

March 15 Alexion Pharmaceuticals Inc said its experimental drug, ALXN1210, met the main goal in a late-stage study in patients with a rare blood disorder.

Select another date: